questionsmedicales.fr
Facteurs biologiques
Pigments biologiques
Pigments biliaires
Bilirubine
Bilirubine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Bilirubine
Analyse sanguine
Tests de laboratoire
Fonction hépatique
Maladies hépatiques
Obstruction biliaire
Symptômes
5
Hyperbilirubinémie
Jaunisse
Maladies hépatiques
Symptômes
Prévention
5
Ictère néonatal
Prévention
Examens médicaux
Fonction hépatique
Maladies hépatiques
Prévention
Alimentation
Santé du foie
Traitements
5
Hyperbilirubinémie
Traitement
Transfusions sanguines
Anémie hémolytique
Corticostéroïdes
Bilirubine
Photothérapie
Ictère néonatal
Chirurgie
Obstruction biliaire
Complications
5
Complications
Lésions hépatiques
Hyperbilirubinémie
Dommages cérébraux
Obstruction biliaire
Infections
Grossesse
Hyperbilirubinémie
Cirrhose
Insuffisance hépatique
Facteurs de risque
5
Facteurs de risque
Maladies hépatiques
Alcoolisme
Hyperbilirubinémie
Infections virales
Hépatite
Surpoids
Maladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bilirubine : Questions médicales les plus fréquentes",
"headline": "Bilirubine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bilirubine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-22",
"dateModified": "2026-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bilirubine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pigments biliaires",
"url": "https://questionsmedicales.fr/mesh/D001654",
"about": {
"@type": "MedicalCondition",
"name": "Pigments biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001654",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Biliverdine",
"alternateName": "Biliverdine",
"url": "https://questionsmedicales.fr/mesh/D001664",
"about": {
"@type": "MedicalCondition",
"name": "Biliverdine",
"code": {
"@type": "MedicalCode",
"code": "D001664",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193.184.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Bilirubine",
"alternateName": "Bilirubin",
"code": {
"@type": "MedicalCode",
"code": "D001663",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Claudio Tiribelli",
"url": "https://questionsmedicales.fr/author/Claudio%20Tiribelli",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Libor Vítek",
"url": "https://questionsmedicales.fr/author/Libor%20V%C3%ADtek",
"affiliation": {
"@type": "Organization",
"name": "4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic."
}
},
{
"@type": "Person",
"name": "Silvia Gazzin",
"url": "https://questionsmedicales.fr/author/Silvia%20Gazzin",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Sri Jayanti",
"url": "https://questionsmedicales.fr/author/Sri%20Jayanti",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Kosuke Koyano",
"url": "https://questionsmedicales.fr/author/Kosuke%20Koyano",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Risk prediction of second primary malignancies in patients after rectal cancer: analysis based on SEER Program.",
"datePublished": "2023-10-12",
"url": "https://questionsmedicales.fr/article/37828423",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12876-023-02974-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative overall survival analysis of chordomas of the base of the skull from the Surveillance, Epidemiology, and End Results (SEER) program between 2000 and 2020.",
"datePublished": "2024-09-25",
"url": "https://questionsmedicales.fr/article/39320522",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10143-024-02815-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of individual-level income predicted from the BRFSS on the association between insurance status and overall survival among adults with cancer from the SEER program.",
"datePublished": "2024-02-06",
"url": "https://questionsmedicales.fr/article/38325026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.canep.2024.102541"
}
},
{
"@type": "ScholarlyArticle",
"name": "Epidemiologic characteristics and a prognostic nomogram for patients with vulvar cancer: results from the Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1975 to 2016.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37477104",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3802/jgo.2023.34.e81"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of proximal and distal gastric neuroendocrine carcinoma based on SEER database.",
"datePublished": "2024-10-29",
"url": "https://questionsmedicales.fr/article/39472636",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-76689-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pigments biologiques",
"item": "https://questionsmedicales.fr/mesh/D010860"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pigments biliaires",
"item": "https://questionsmedicales.fr/mesh/D001654"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bilirubine",
"item": "https://questionsmedicales.fr/mesh/D001663"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bilirubine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bilirubine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-20",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bilirubine",
"description": "Comment mesurer le taux de bilirubine ?\nQuels tests diagnostiques sont utilisés ?\nQu'indique un taux élevé de bilirubine ?\nQuelle est la différence entre bilirubine directe et indirecte ?\nQuels symptômes peuvent nécessiter un test de bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=SEER+Program#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bilirubine",
"description": "Quels sont les symptômes d'une hyperbilirubinémie ?\nLa bilirubine affecte-t-elle la peau ?\nQuels signes indiquent une maladie hépatique ?\nLa bilirubine peut-elle causer des démangeaisons ?\nComment la bilirubine affecte-t-elle l'urine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=SEER+Program#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bilirubine",
"description": "Comment prévenir l'ictère néonatal ?\nQuels examens réguliers sont recommandés ?\nComment éviter les maladies hépatiques ?\nLes vaccinations sont-elles importantes ?\nComment une alimentation saine aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=SEER+Program#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bilirubine",
"description": "Comment traiter une hyperbilirubinémie ?\nLes transfusions sanguines sont-elles nécessaires ?\nQuels médicaments peuvent réduire la bilirubine ?\nLa photothérapie est-elle efficace ?\nQuand envisager une chirurgie pour la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=SEER+Program#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bilirubine",
"description": "Quelles complications peuvent survenir avec une bilirubine élevée ?\nL'hyperbilirubinémie peut-elle causer des dommages cérébraux ?\nQuels sont les risques d'une obstruction biliaire ?\nComment l'hyperbilirubinémie affecte-t-elle la grossesse ?\nQuelles sont les conséquences d'une maladie hépatique avancée ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=SEER+Program#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bilirubine",
"description": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?\nL'alcoolisme est-il un facteur de risque ?\nLes infections virales influencent-elles la bilirubine ?\nLe surpoids est-il un facteur de risque ?\nLes médicaments peuvent-ils affecter la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=SEER+Program#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le taux de bilirubine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le taux de bilirubine est mesuré par une analyse sanguine."
}
},
{
"@type": "Question",
"name": "Quels tests diagnostiques sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la bilirubine totale et directe, ainsi que des tests hépatiques."
}
},
{
"@type": "Question",
"name": "Qu'indique un taux élevé de bilirubine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé peut indiquer une maladie hépatique, une obstruction biliaire ou une anémie."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre bilirubine directe et indirecte ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bilirubine directe est soluble dans l'eau, tandis que l'indirecte ne l'est pas."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent nécessiter un test de bilirubine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme jaunisse, fatigue ou douleurs abdominales peuvent nécessiter un test."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hyperbilirubinémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, urine foncée, selles claires et démangeaisons."
}
},
{
"@type": "Question",
"name": "La bilirubine affecte-t-elle la peau ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un excès de bilirubine peut provoquer un jaunissement de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie hépatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la fatigue, l'ictère et des douleurs abdominales peuvent indiquer une maladie hépatique."
}
},
{
"@type": "Question",
"name": "La bilirubine peut-elle causer des démangeaisons ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de bilirubine peut provoquer des démangeaisons cutanées."
}
},
{
"@type": "Question",
"name": "Comment la bilirubine affecte-t-elle l'urine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé de bilirubine peut rendre l'urine foncée, semblable à celle du thé."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'ictère néonatal ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'ictère néonatal peut être prévenu par une surveillance attentive des nouveau-nés et une alimentation adéquate."
}
},
{
"@type": "Question",
"name": "Quels examens réguliers sont recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction hépatique sont recommandés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Comment éviter les maladies hépatiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'alcool, maintenir un poids santé et se faire vacciner contre l'hépatite aide à prévenir les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre l'hépatite A et B sont cruciales pour prévenir les infections hépatiques."
}
},
{
"@type": "Question",
"name": "Comment une alimentation saine aide-t-elle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée aide à maintenir la santé du foie et à prévenir l'accumulation de bilirubine."
}
},
{
"@type": "Question",
"name": "Comment traiter une hyperbilirubinémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la cause sous-jacente, comme des médicaments ou une intervention chirurgicale."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas d'anémie hémolytique, des transfusions peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent réduire la bilirubine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les corticostéroïdes peuvent être utilisés pour traiter certaines conditions."
}
},
{
"@type": "Question",
"name": "La photothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photothérapie est souvent utilisée pour traiter l'ictère néonatal en réduisant la bilirubine."
}
},
{
"@type": "Question",
"name": "Quand envisager une chirurgie pour la bilirubine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être envisagée en cas d'obstruction biliaire ou de maladies hépatiques graves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une bilirubine élevée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des lésions hépatiques, des troubles neurologiques et des infections."
}
},
{
"@type": "Question",
"name": "L'hyperbilirubinémie peut-elle causer des dommages cérébraux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperbilirubinémie sévère peut entraîner des dommages cérébraux, surtout chez les nouveau-nés."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une obstruction biliaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des douleurs abdominales et des lésions hépatiques."
}
},
{
"@type": "Question",
"name": "Comment l'hyperbilirubinémie affecte-t-elle la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des complications pour la mère et le fœtus, nécessitant une surveillance étroite."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une maladie hépatique avancée ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies hépatiques, des infections et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'alcoolisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'alcoolisme peut endommager le foie et augmenter le risque d'hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les infections virales influencent-elles la bilirubine ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections comme l'hépatite peuvent augmenter les niveaux de bilirubine."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut contribuer à des maladies hépatiques et à une hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils affecter la bilirubine ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec le métabolisme de la bilirubine et augmenter ses niveaux."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2026
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
4 publications dans cette catégorie
Affiliations :
4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Publications dans "Bilirubine" :
4 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Faculty of Medicine, University of Hasanuddin, Makassar 90245, Indonesia.
Molecular Biomedicine Ph.D. Program, Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neonatology Department, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neurology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, 34139 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Italian Liver Fondation, Bldg. Q-AREA Science Park Basovizza, SS14, km. 163,5, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Hepatic Surgery and Liver transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Bilirubine" :
This study will focus on exploring the clinical characteristics of rectal cancer (RC) patients with Second Primary Malignancies (SPMs) and constructing a prognostic nomogram to provide clinical treatm...
We determined the association between risk factors and overall survival (OS) while establishing a nomogram to forecast the further OS status of these patients via Cox regression analysis. Finally, we ...
Nine parameters were identified to establish the prognostic nomogram in this study, and, the C-index of the training set and validation set was 0.691 (95%CI, 0.662-0.720) and 0.731 (95%CI, 0.676-0.786...
We systematically explored the clinical characteristics of SPMs after RC and constructed a satisfactory nomogram....
Chordomas of the skull base are rare, slow growing, locally invasive cancers with limited long-term survival analysis reported in the literature. We seek to provide comparative survival analysis of pa...
Among patients with cancer in the United States, Medicaid insurance is associated with worse outcomes than private insurance and with similar outcomes as being uninsured. However, prior studies have n...
The Surveillance, Epidemiology, and End Results (SEER) database was queried for 18-64 year-old individuals with cancer from 2014-2016. Individual-level income was imputed using a model trained on Beha...
A total of 416,784 cases in SEER were analyzed. The 1-yr OS for patients with private insurance, Medicaid insurance, and no insurance was 88.7%, 76.1%, and 73.7%, respectively. After adjusting for all...
Income, rather than Medicaid status, may drive poor cancer outcomes in the low-income and Medicaid-insured population. Medicaid insurance coverage may improve cancer outcomes for low-income individual...
To elucidate clinical characteristics and build a prognostic nomogram for patients with vulvar cancer....
The study population was drawn from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly assigned to training and validation sets. Cox proportional hazards model and...
A total of 20,716 patients were included in epidemiological analysis, of whom 7,025 patients were selected in survival analysis, including 4,215 and 2,810 in training and validation sets, respectively...
The nomogram showed accurate prognostic prediction in OS and CSS for vulvar cancer, which could provide guidance to clinical practice....
The occurrence of gastric neuroendocrine carcinoma (GNEC) is on the rise, and its prognosis is extremely poor. We compared survival outcomes between distal and proximal GNEC and developed a nomogram i...
Renal medullary carcinoma (RMC) is an aggressive and rare renal malignancy that predominantly affects Black patients but is also found in individuals of other ethnicities. To date, only a few hundred ...
We utilized the Surveillance, Epidemiology, and End Results Program (SEER) database 18 registries to retrieve demographic and clinical information on patients with RMC between 1996 and 2018. A multiva...
We identified 100 patients diagnosed with renal medullary carcinoma using the SEER Database in the study period. The mean age was 28.0 ± 12.0 (95% confidence interval [CI] 25.7-30.4). Among the patien...
These data confirm that RMC is a rare disease that disproportionately affects Black patients. The prognosis appears to be substantially worse for Black subjects diagnosed with this cancer than non-Bla...
Multiple myeloma (MM) is exceedingly rare in adolescents and young adults (AYAs) < 45 years of age....
Real-world data from ASCO's CancerLinQ Discovery...
A total of 1946 AYA MM patients from SEER and 1334 from CancerLinQ were included. In terms of SPMs, AYAs were more likely to develop ALL (RR 2.6, P = .003) and AML (RR 1.7, P = .034), and less likely ...
This analysis highlights some unique characteristics of AYA MM patients in the United States in the modern era....
Primary pulmonary sarcoma (PPS) is a rare and poor prognostic malignancy that results from current clinical studies are lacking. Our study aimed to investigate the prognostic factors of PPS and to con...
This study aimed to develop nomogram predicting overall survival (OS) of patients with peritoneal mesothelioma (PeM) using data from Surveillance, Epidemiology, and End Results (SEER) database and a C...
1,177 PeM patients from the SEER database were randomized into training and internal validation cohorts at a 7:3 ratio. An external validation cohort consisting of 109 patients was enrolled from a Chi...
The nomogram, incorporating age, gender, histological type, T stage, M stage, and surgical status, demonstrated strong predictive capability with C-index values of 0.669 for the training cohort, 0.668...
The nomogram provide a reliable tool for predicting the survival in PeM patients, facilitating more informed treatment decisions. Key independent prognostic factors include gender, age, surgical inter...
Choroid plexus tumors (CPT) are rare and highly vascularized neoplasms that have three histologically confirmed diagnoses, including choroid plexus papilloma, atypical choroid plexus papilloma, and ch...